



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:

Sheryl Seapy
Pure Communications, Inc.
(949) 608-0841

Foundation Medicine to Present Data on Proprietary Approach to Optimizing Next-Generation Cancer Genome Sequencing Platform to Enable Clinical Application at RECOMB 2011

Company Also Will Discuss Potential Diagnostic Applications for Next-Generation Sequencing of Cancer Genomes at AACR Annual Meeting in April

CAMBRIDGE, Mass. – March 23, 2011 – [Foundation Medicine, Inc.](#), a personalized cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine clinical care, today announced that the company will be presenting new methods and data highlighting its progress in optimizing cancer genome analysis using next-generation sequencing (NGS) in routinely-collected patient tissues at the RECOMB 2011 Satellite Workshop on Computational Cancer Biology being held March 26-27, 2011 in Vancouver, B.C.

Foundation Medicine senior computational biologist Roman Yelensky, Ph.D., will present on “A Bayesian approach for sensitive detection of somatic mutations from next-generation sequencing of clinical cancer specimens,” at 4:25 p.m. (PDT) on Saturday, March 26, 2011. Dr. Yelensky’s presentation will highlight the company’s progress in increasing the reliability of data generated by NGS-based cancer genome analysis. This reliability increasingly will be necessary as physicians incorporate NGS-based cancer genome analysis as an integral part of optimal patient care. Foundation Medicine is developing a comprehensive test that will help inform optimal treatment decisions based on the genomic alterations associated with a patient’s cancer.

In addition, Foundation Medicine will participate in two scientific sessions during the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 being held April 2-6, 2011 in Orlando, Fla. Philip Stephens, Ph.D., Foundation Medicine executive director, research and product development, will discuss “Novel insights into cancer development and progression revealed by whole genome structural variation characterization” during the session, “Understanding the Tumor Genome Through Next-Generation Sequencing,” scheduled for Saturday, April 2, 2011 at 2:30 p.m. (EDT).

Dr. Stephens also will participate in the AACR Annual Meeting MICR Scientific Symposium, “Can Advancing our Understanding of the Human Genome Reduce Breast Cancer Health Disparities?” on Tuesday, April 5, 2011 at 10:30 a.m. (EDT).

“We are excited to share with the scientific and medical communities our progress in overcoming the inherent complexities in producing reliable, clinical-grade cancer diagnostic information using next-gen sequencing,” said Alexis Borisy, founding CEO of Foundation Medicine. “By combining genomic data and publicly-available scientific and medical information in an easy-to-use format, Foundation Medicine seeks to help clinicians make the best possible treatment recommendations for each cancer patient.”

About Foundation Medicine

Foundation Medicine is dedicated to the development of a comprehensive diagnostic test that improves cancer care by helping physicians to personalize treatment for their patients. Foundation Medicine’s laboratory test is being designed to accommodate a dynamic landscape of cancer genome information and a growing repertoire of treatment options and clinical research opportunities. Foundation Medicine’s test will help physicians make prompt and informed determinations about the best cancer treatments and clinical trial options for each patient, taking into account each patient’s unique cancer-associated alterations alongside publicly available scientific and medical information. The company’s founding advisors are world leaders in genome technology, cancer biology and medical oncology; they, alongside clinicians, biotech and molecular diagnostics industry leaders, are working to harness emerging technologies to develop unparalleled tests that will identify and interpret an ever-growing set of actionable genomic alterations, truly enabling personalized cancer medicine. For more information, please visit the company’s website at www.foundationmedicine.com.

###